President Donald Trump is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut costs associated with prescription drugs.

Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...

Great. Thank you for coming, everybody. I'm James Gordon, Barclays European pharma and biotech analyst. And today, I've got the pleasure of hosting a fireside with GSK. So we're going to hear from GSK ...

As Congress mulls whether to follow President Donald Trump’s orders for a most-favored-nation drug-pricing policy, biotech firm executives are starting to speak out against the measure.

GSK and Alfasigma have signed a licensing agreement granting Alfasigma worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational IBAT inhibitor for the ...

Speaking at a recent meeting of the British Pharmacological Society in Brighton, UK, Christine Mummery described how using embryonic stem cells to create human heart cells could b ...

Debevoise & Plimpton LLP announced the launch of STAAR 2.0, an enhanced version of its award-winning* client-facing AI platform designed to help in-house legal and compliance teams evaluate, govern, ...

GSK struck a $950 million deal to buy Canada’s 35Pharma, a biopharmaceutical company developing cardiopulmonary treatments, as the U.K. drugmaker seeks to bolster its exposure to diseases linked to ...

(RTTNews) - British drug major GSK plc (GSK, GSK.L) reported Wednesday higher profit and revenues in its fourth quarter, and issued fiscal 2026 outlook, expecting increase in core profit and turnover.

GSK gains global rights to ozureprubart, excluding parts of Asia RAPT's ozureprubart targets antibody causing allergic reactions Deal is GSK's first major acquisition under new CEO Luke Miels The deal ...

The growing scourge of food allergies drove U.K. heavyweight pharmaceutical GSK to announce a $2.2 billion deal on Tuesday. GSK said it was buying U.S.-listed RAPT Therapeutics for $2.2 billion, or ...

GSK plc (NYSE: GSK) on Tuesday agreed to acquire RAPT Therapeutics Inc. (NASDAQ: RAPT) for $58.00 per share. The deal consideration is equivalent to an estimated aggregate equity value of $2.2 billion ...